Patients with locally advanced cervical cancer treated with definitive (chemo)radiation cervical cancer hyaluronic acid spacer rectal toxicity
Conditions
Interventions
At the time of first brachytherapy, hyaluronic acid 6-10 ml will be injected between the rectum and cervix at the posterior wall of the vagina with transrectal ultrasound guidance. ,No hyaluronic acid
Experimental Drug,No Intervention No treatment
Hyaluronic acid spacer,Standard treatment
Sponsors
Ratchadapiseksompotch Research Fund
Eligibility
Sex/Gender
Female
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Positive biopsy showing squamous cell carcinoma, adenocarcinoma, or adenosquamous cell carcinoma of the uterine cervix 2. Cancer of the cervix is considered suitable for curative treatment with definitive radio-(chemo)therapy
Exclusion criteria
Exclusion criteria: 1. Posterior vaginal involvement 2. Other primary malignancies except basal cell carcinoma of the skin 3. Small cancer neuroendocrine cancer, melanoma, and other rare cancers in the cervix 4. Rectal invasion 5. Metastatic disease above and beyond the retroperitoneal para-aortic L1-L2 interspace 6. Previous pelvic or abdominal radiotherapy 7. Previous total or partial hysterectomy 8. Contraindications to MRI 10. Coagulopathy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Dosimetric data of the rectum At the RT completion D2cc of the rectum | — |
Secondary
| Measure | Time frame |
|---|---|
| Acute toxicity incidence During treatment and at 3 months after RT CTCAE version 5.0,Late toxicity incidence at 6 months, 12 months and 24 months after RT CTCAE version 5.0,Quality of life At time of RT completion and 12 months after RT EORTC QLQ-C30, CX24 | — |
Countries
Thailand
Contacts
Public ContactNapapat Amornwichet
Division of Radiation Oncology, Department of Radiology, Faculty of Medicine, Chulalongkorn University
Outcome results
None listed